Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Juno Therapeutics, Inc. v. Kite Pharma, Inc.
Case Number:
20-1758
Court:
Nature of Suit:
830 Patent Infringement (Fed. Qst.)
Companies
Sectors & Industries:
-
September 01, 2020
Kite Pharma Wants Fed. Circ. To Nix Juno's $1.2B Patent Win
Gilead unit Kite Pharma is asking the Federal Circuit to wipe out a $1.2 billion judgment in Juno Therapeutics Inc.'s favor in a patent case over Kite's cancer treatment Yescarta, saying the judgment "reward[s] Juno for Kite's success in solving the very problems Juno could not."
- ← Previous
- 1
- 2
- Next →